| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | MANZANITA PHARMACEUTICALS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44CA295214 | Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer | 000 | 1 | NIH | 10/24/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $905,526 ) |
| | 2024 | 2024 | MANZANITA PHARMACEUTICALS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44CA295214 | Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer | 000 | 1 | NIH | 9/6/2024 | $905,526 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2018 | MANZANITA PHARMACEUTICALS INC | 2995 WOODSIDE RD STE 400 | WOODSIDE | CA | 94062-2448 | SAN MATEO | USA | R44CA180745 | Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent | 000 | 3 | NIH | 12/16/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | MANZANITA PHARMACEUTICALS INC | 2995 WOODSIDE RD STE 400 | WOODSIDE | CA | 94062-2448 | SAN MATEO | USA | R44CA180745 | Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent | 000 | 3 | NIH | 7/29/2020 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $752,754 ) |
| | 2018 | 2018 | MANZANITA PHARMACEUTICALS INC | 2995 WOODSIDE RD STE 400 | WOODSIDE | CA | 94062-2448 | SAN MATEO | USA | R44CA180745 | Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent | 000 | 3 | NIH | 8/23/2018 | $752,754 |
|
| Issue Date FY: 2017 ( Subtotal = $1,220,153 ) |
| | 2017 | 2017 | MANZANITA PHARMACEUTICALS INC | 2995 WOODSIDE RD STE 400 | WOODSIDE | CA | 94062-2448 | SAN MATEO | USA | R44CA180745 | Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent | 000 | 2 | NIH | 9/25/2017 | $1,220,153 |
|
| Issue Date FY: 2013 ( Subtotal = $288,301 ) |
| | 2013 | 2013 | MANZANITA PHARMACEUTICALS INC | 2995 WOODSIDE ROAD | WOODSIDE | CA | 94062 | SAN MATEO | USA | R43CA180745 | IN VIVO FEASIBILITY OF A PERIPHERAL NERVE IMAGING AGENT | 000 | 1 | NIH | 8/19/2013 | $288,301 |
|
|
